Antagonist targeting microRNA-146a protects against lithium-pilocarpine-induced status epilepticus in rats by nuclear factor-κB pathway

HUILONG ZHANG1*, YUN QU2* and AIHUA WANG3

Departments of 1Neurology and 2Emergency, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000; 3Department of Neurology, Qianfoshan Hospital Affiliated to Shandong University, Jinan, Shandong 250014, P.R. China

Received February 15, 2017; Accepted December 5, 2017

DOI: 10.3892/mmr.2018.8465

Abstract. Previous studies have indicated that nuclear factor-κB (NF-κB) has an important role in the pathogenesis of epilepsy. The aim of the present study was to evaluate the expression of microRNA (miRNA)-146a, phosphorylated (p)-P65/P65, B-cell lymphoma-2 (Bcl-2)/Bcl-2-associated X protein (Bax) and pro-inflammatory cytokines, such as interleukin (IL)-6, IL-1β and tumor necrosis factor (TNF-α) in the brain tissue of rats with epilepsy. Sprague-Dawley rats were used to establish the epilepsy model using the lithium-pilocarpine method. The expression of miR-146a, pro-inflammatory cytokines, P-glycoprotein (P-gp), Bcl-2/Bax and p-P65/P65 were assessed by reverse transcription-semi-quantitative polymerase chain reaction, enzyme-linked immunosorbent assay and western blotting, respectively. Hematoxylin and eosin staining was used to determine the pathology of epilepsy. The current findings revealed that the expression of miR-146a was greater in the model group compared with the control group, and that the expression of miR-146a reached a maximum at 7 days post-treatment. The expression levels of IL-1β, IL-6 and TNF-α were significantly reduced in the miR-146a antagonist group when compared with the model group. Additionally, the expression levels of P-gp and p-P65/P65 were significantly reduced following the addition of the miR-146a antagonist, whereas the expression levels of Bcl-2/Bax significantly increased under the same conditions. Therefore, the NF-κB pathway and miR-146a may be potential therapeutic targets in the treatment of epilepsy.

Introduction

Epilepsy is a serious, long-term and debilitating brain disorder, identifiable by paroxysmal bursts of activity within cortical neurons, which affects approximately 1% of the world population (1,2). Although epilepsy frequently develops in childhood, its symptoms may last a lifetime (3). Epilepsy is characterized by a predisposition to recurring episodes of seizures and abnormally synchronized neuronal discharges with the potential to disrupt the function of the brain region from which they originate, or through which they pass (1). Despite currently available antiepileptic drugs and surgeries for focal epilepsy being available, both clinical treatments have some side effects, including headache, dizziness, fatigue and ataxia. Additionally, >20% of all patients with epilepsy continue to have the symptoms following treatment (4,5). Therefore, the identification of new biological markers for treatment against epilepsy is of great importance. In recent years, there has been a number of studies investigating molecular causes of epilepsy (6-9). A previous study suggested the involvement of microRNAs (miRNAs) in the lesion of epilepsy (6). miRNAs are single-stranded molecules, between 18-24 nucleotides in length, that block the expression of protein-coding genes at the post transcriptional level by directing translational repression or mRNA destabilization, or a combination of the two (7). Many post transcriptional inflammation-associated miRNAs, such as the brain-enriched miRNA (miR)-146a, have been previously identified to be involved in the regulation of inflammatory responses in epileptic rats and adult patients (8,9).

The nuclear factor-κB (NF-κB) pathway is an important intracellular signaling pathway involved in the early stress response (10-12). A previous study suggested that NF-κB acts as a key point of convergence for multiple stress signals, including intracellular Ca2+ changes, pro-inflammatory cytokines and oxidative stress (10). The pathway is also involved in the modulation of neuronal excitability and seizure susceptibility (13). Additionally, downstream events activated by NF-κB, such as inflammation and oxidative stress, are also known to be activated by seizure activity (14,15).
The present study induced an epilepsy animal model using the lithium-pilocarpine method. The expression of miR-146a was detected using reverse transcription-semi-quantitative polymerase chain reaction (RT-sqPCR). The expression levels of pro-inflammatory cytokines, including interleukin (IL)-1β, IL-6 and tumor necrosis factor-α (TNF-α), were determined using an ELISA. Additionally, the protein expression levels of P-glycoprotein (P-gp), B-cell lymphoma-2 (Bcl-2)/Bcl2-associated X (Bax) and phosphorylated (p)-P65/P65 were quantified using western blot analysis. The findings of the present study may aid the evaluation of miR-146a regulation as a potential new anti-epilepsy therapy, and suggests that miR-146a antagonist treatment of epilepsy may be associated with NF-κB pathway.

Materials and methods

Animals. A total of 72 adult male Sprague-Dawley rats (Weitongliahua Biomart, Beijing, China), weighing 180-220 g, 6-8 weeks were housed in a temperature (24±0.5°C) and 12-h light-dark cycle with a 50-60% humidity and had free access to food and water. Prior to the experiments, the animals were allowed to habituate to the housing facilities for 1 week. The present study was conducted with approval from the Animal Ethics Committee of the affiliated Yantai Yuhuangding Hospital of Qingdao University (Yantai, China).

Epilepsy induction. In order to induce status epilepticus (SE), rats were intraperitoneally (i.p.) injected 127 mg/kg with lithium chloride (CAS: 7447-41-8; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), followed 20 h later by anatoprine (Tianjin Kaitong Chemical Reagent Co., Ltd., Tianjin, China) i.p. (0.1 mg/kg) injection and 30 min later by pilocarpine hydrochloride (cat. no. P6503-5G, Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) treatment (40 mg/kg; i.p.). SE was characterized by continuous limbic seizures 30 min after the last treatment. The severity of seizures was evaluated using the Racine scale (16): 0, No response; 1, motor arrest and twitching; 2, chewing and head bobbing; 3, forelimb clonus; 4, forelimb clonus and rearing; and 5, rearing and falling. Rats exhibiting continuous seizures at stage V of the Racine scale were used for the subsequent experiments, were then divided into two sections. Section I, consisted of two groups: i) 8 Naive rats were used as control; and ii) 40 SE rats were used to evaluate the expression of miR-146a. Section II, consisted of three groups: i) 8 naive rats were used as control; ii) SE model group n=8; and iii) 1 nmol miR-146a inhibitor-treated (Guangzhou RiboBio Co., Ltd., Guangzhou, China) group (IN group). The rats belonging to the IN group were treated with 1 nmol miR-146a inhibitor 2 h post-pilocarpine injection.

RT-sqPCR. Animals were sacrificed following deep anesthesia with an i.p. injection of 10% chloral hydrate (500 mg/kg) at day 1, 3, 7, 14 and 30 following SE induction. Following decapitation, the brain was removed as previously described (17) for RNA isolation. Total RNA was extracted with TRIzol reagent (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and both the concentration and the purity of RNA were then determined at 260/280 nm using a NanoDrop spectrophotometer. Isolated RNA (1 µg) was then subjected to cDNA synthesis. cDNA synthesis was conducted in a 14 µl reaction buffer, containing 1 µl reverse transcriptase (50 U) and 1 µl oligo (dT) primer, according to manufacturer's protocol (Takara Biotechnology Co., Ltd., Dalian, China). The following temperature protocol was used for the reverse transcription: 37°C for 15 min, 85°C for 5 sec and 4°C until subsequent use for qPCR. The sequences of the primers for qPCR wereas follows: miRNA-146a, forward (F), 5'-CAGTCCGGTCTCGGAGT-3' and reverse (R), 5'-GGG TGAGAAGCTAATCTCA-3'; U6 F, 5'-GCTTGGCGACGA CATATACTAAAT-3' and R, 5'-CGGTCTACGAATTTG CGTTGTCA-3'. Reaction conditions were as follow: 95°C for 30 sec, followed by 35 cycles of 95°C for 10 sec, 60°C for 15 sec and 72°C for 15 sec. Each 20 µl reaction system consisted of 2 µl cDNA, 10 µl SYBR Premix Ex Taq II (Sangong Biotech Co., Ltd., Shanghai, China) and 10 µmol/l of both forward and reverse primers (Sangong Biotech Co., Ltd.). U6 was used to normalize the mRNA. The results were analyzed on an 1% agarose gel (Sangong Biotech Co., Ltd.) with ethidium bromide and the relative intensity of the bands was determined using Image J software (National Institutes of Health, Bethesda, MD, USA).

Histopathological analysis. The hippocampus was dehydrated in increasing concentrations of ethanol, rinsed with Histoclear (National Diagnostics, Atlanta, GA, USA), embedded in paraffin and then cut on a microtome into 5-µm thick slices. Following dewaxing, slides were boiled for 48 h at 45°C and then for 1 h at 60°C. The sections were stained with hematoxylin and eosin for 10 and 5 min respectively at room temperature. All stained sections were then assessed under a light microscope (magnification, x400).

Western blot analysis. The brain tissue samples were homogenized in lysis buffer (20 mMTris, 1% Triton-X-100, 0.05% SDS, 5 mg of sodium deoxycholate, 150 mMNaCl and 1 mM PMSF) containing a mixture of protease and phosphatase inhibitors. The protein concentrations were then determined using a Bicinchoninic acid Protein Assay reagent kit (Beyotime Institute of Biotechnology, Shanghai, China). Equal quantity of protein (40 µg/lane) were separated by 10% SDS-PAGE and then transferred to polyvinylidenedifluoride membranes. The nonspecific binding of antibodies was blocked with 5% non-fat dried milk in PBS, then incubated with the following primary antibodies: Rabbit monoclonal Bcl-2 (1:500; cat. no. 3498, Cell Signaling Technology, Inc., Danvers, MA, USA), rabbit monoclonal Bax (1:500; cat. no. 5023; Cell Signaling Technology, Inc.), rabbit monoclonal P-gp (1:500; cat. no. ab170964; Abcam, Cambridge, UK), rabbit monoclonal p-P65 (1:500; cat. no. 3033; Cell Signaling Technology, Inc.), rabbit monoclonal P65 (1:500; cat. no. 59674; Cell Signaling Technology, Inc.) at 4°C overnight. Following incubation with the horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G secondary antibody (1:5,000; cat. no. SC-2004; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) at 4°C for 1 h and developed with electrochemiluminescence (ECL) Western Blotting Substrate (BD Biosciences, Franklin Lakes, NJ, USA). Data was analyzed using Quantity One 1D image analysis software (version 4.4; Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Enzyme-linked immunosorbent assay (ELISA). ELISA kits for rat IL-1β (cat. no. PI303; Beyotime Institute of Biotechnology), TNF-α (cat. no. PT516; Beyotime Institute of Biotechnology) and IL-6 (cat. no. PI328; Beyotime Institute of Biotechnology) were used to determine cytokine levels in cerebrospinal fluid (CSF) following the manufacturer's protocols. The plates were quantified at 450 nm using a microplate reader.

Statistical analysis. Data are expressed as mean ± standard deviation. Statistical differences were evaluated using SPSS version 19.0 (IBM Corporation, Armonk, NY, USA). Statistical analysis was performed using one-way analysis of variance. P<0.05 was considered to indicate a statistically significant difference.

Results

RT-qPCR. miR-146a expression levels were significantly upregulated in the brain tissue of the SE group when compared with control group at day 1, 3, 7, 14 and 30 (P<0.05; P<0.01; Fig. 1). The upregulation of miR-146a expression reached a maximum at the day 7 following pilocarpine treatment (P<0.01). The rats were treated with the miR-146a inhibitor, the expression of miR-146a was significantly reduced (Fig. 2; P<0.01). However, no significant difference between the control group and the IN group was identified (P>0.05).

Histopathological analysis. Examination of hippocampal CA3 and CA4 regions in the control group revealed compactly arranged and healthy pyramidal cells with clear nuclei, and intact cell membranes (Fig. 3A). Compared to the control group, hematoxylin and eosin staining of the model group 7 days post-pilocarpine treatment displayed numerous shrunken neurons, neuronal cell loss, disordered tissue structure in hippocampal CA3 and CA4 are as and abnormal cell morphology (Fig. 3B). Rats treated with the miR-146a inhibitor
Figure 5. miR-146a inhibitor reduced (A) TNF-α, (B) IL-1β and (C) IL-6 expression levels in CSF following pilocarpine treatment. *P<0.05, **P<0.01 vs. control group. IN, inhibitor group. TNF-α, tumor necrosis factor-α; IL, interleukin; CSF, cerebrospinal fluid.
exhibited significantly reduced levels of neuronal cell loss and other morphological signs of damage (Fig. 3C).

**Western blot analysis.** P-gp and p-P65/P65 expression was significantly increased in the hippocampus of the model group compared with the control group (Fig. 4; P<0.01). Compared with model group, the miR-146a inhibitor-treated group (IN group) significantly downregulated P-gp and p-P65/P65 expression. Conversely, the expression level ratio of Bcl-2/Bax in hippocampal tissues in the model group was significantly lower when compared with the control group (P<0.01; Fig. 4B). The treatment of miR-146a antagonist significantly reversed this as Bcl-2/Bax ratio was increased in the IN group when compared with model group (P<0.01). These findings suggest that the miR-146a inhibitor reduces the expression of P-gp and p-P65/P65 and increases the expression of Bcl-2/Bax in rats.

**Enzyme-linked immunosorbent assay (ELISA).** Previous studies have demonstrated that pro-inflammatory cytokines are involved in SE (18-20). Therefore, the current study aimed to investigate the alterations in pro-inflammatory cytokine expression levels in CSF. As presented in Fig. 5, significant increases in TNF-α, IL-1β, and IL-6 expression levels in CSF of model rats when compared with the control group were observed. However, the addition of the miR-146a inhibitor reversed the effect of pilocarpine treatment by preventing the increase in the expression levels of TNF-α, IL-1β and IL-6 (Fig. 5; P<0.05). These findings suggest that the miR-146a antagonist attenuates the expression of TNF-α, IL-1β and IL-6 in the CSF of SE rats.

**Discussion**

miR-146a is a typical multifunctional miR and has a key role in several biological processes. miR-146a was upregulated during epileptogenesis in an animal model and patients (4,21). Aronica et al reported an altered expression pattern of miR-146a in epileptic rats and in the temporal lobe of epilepsy patients, and demonstrated high expression levels of miR-146a in the latent and chronic stages of disease in the rat model and human tissues (22). The present study investigated the dynamic expression of miR-146a in a lithium-pilocarpine-induced epilepsy rat model and the possible use of miR-146a as a target against epilepsy. The present findings revealed a marked upregulation of miR-146a in the model group, whereas rats treated with the miR-146a antagonist had reduced miR-146 expression levels. This finding was consistent with that reported by the Hu et al study (23).

The transcription factor, NF-κB is an important regulator of immune and inflammatory processes, and has previously been described to be involved in neuropathological processes, including seizures and epilepsy (24,25). Furthermore, a previous study demonstrated that NF-κB is activated in response to convulsion stimulation in rodent models (26). When NF-κB is activated, it binds to the promoter domain of the target genes through DNA NF-κB sequences. A number of cytokines and chemokines are involved in this pathway following NF-κB activation (27). Previous study has identified the P-glycoprotein (P-gp) as a regulator of the NF-κB signaling pathway at the blood-brain barrier (BBB) in a number of pathogenic scenarios (28). It has previously been suggested that antiepileptic drugs may use P-gp as an efflux pump, which is located at the endothelial cell membrane in the brain (29). The expression of P-gp in the brain is increased under prolonged seizure conditions, such as SE or frequent spontaneous seizures (30). In the present study, the expression levels of NF-κB and P-gp were markedly increased in lithium-pilocarpine-induced epilepsy; however, the addition of the miR-146a inhibitor was able to block this effect. The findings obtained by the current study are in line with those found in previous studies. Experimental models and clinical studies have confirmed that a prolonged seizure or SE may lead to neuronal death in the brain (31). The underlying mechanism by which neurons die following brain injury, such as a stroke or SE, has revealed the involvement of apoptosis in neuronal cell death (32). Apoptosis is regulated by several signaling pathways, in which the Bcl-2 protein family has an important role (33). Proteins of particular interest within the Bcl-2 family are Bcl-2, an anti-apoptotic protein in which may prevent cell death and Bax, a homolog of Bcl-2 which may promote apoptosis (34). The Bcl-2/Bax ratio has previously been used to determine the anti-apoptosis capability (35). Treatment with the miR-146a inhibitor may protect neurons from lithium-pilocarpine-induced toxicity and reverse lithium-pilocarpine-induced neuronal injury, partially through inhibition of the aforementioned apoptotic pathways.

NF-κB is an important inflammatory regulator, which is responsible for the activation of downstream pro-inflammatory cytokines, including IL-1β, IL-6 and TNF-α, in SE models or patients (36). Previous studies have revealed that inflammation contributes to epileptogenesis (18-20). Ravizza et al (18) identified that expression of IL-1β was markedly induced in the acute stage 4 h following SE. Furthermore, it has been revealed that seizures may allow circulating proteins to enter the brain through the BBB (6). IL-6 is a cytokine that is upregulated following different types of tissue trauma and inflammation. IL-6 and TNF-α levels were observed as being upregulated in the SE model and in patients following a seizure (37,38). The present study demonstrated an upregulation of TNF-α, IL-1β and IL-6 in the model group when compared with the control group. Additionally, it was determined that treatment with miR-146a may significantly reduce the expression levels of pro-inflammatory cytokines compared to those observed in the model group. The findings of the present study therefore suggest that activation of the cytokine network is associated with epilepsy.

The present study may not explicitly explain the enacting mechanism of the miR-146a inhibitor; however, the current findings may provide a novel rapeutic target for antiepileptic therapy. Further investigation is required to establish whether the change in expression of pro-inflammatory cytokines and the altered activity of the NF-κB pathway occur via distinct or related mechanisms in the SE model.

In conclusion, the use of miR-146a inhibitor for the blocking of the pathogenic activation of the NF-κB pathway contributing to epileptogenesis in the SE brain may have a protective function. The current study demonstrated that there was an upregulation
of miR-146a expression in lithium-pilocarpine-induced epilepsy. The current findings also demonstrated an upregulation of miR-146a expression associated with seizures. The expression patterns of pro-inflammatory cytokines, including TNF-α, IL-1β and IL-6 and their regulator, NF-κB, suggest an interactive relationship. The findings of the current study support the proposal that pro-inflammatory cytokines and the NF-κB pathway have a role in the pathogenesis of SE development. Additionally, the findings of the present study suggest that modulation of miR-146a expression by using an inhibitor may act as a potential target for antiepileptic therapy.

References